Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.94% | -26.34% | 1.06% | 0.59% | 40.91% |
| Total Depreciation and Amortization | -14.68% | 44.18% | -10.00% | 12.30% | -9.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.51% | 100.75% | -58.55% | 387.93% | 70.56% |
| Change in Net Operating Assets | -224.39% | 112.00% | -66.60% | -1,237.35% | -95.47% |
| Cash from Operations | -0.52% | 41.39% | -32.12% | -25.67% | -2.88% |
| Capital Expenditure | -281.49% | -4.73% | -291.67% | -58.82% | 86.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -285.84% | -3.55% | -338.98% | 360.29% | 86.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -2.26% | -21,848.29% | -0.99% |
| Issuance of Common Stock | -98.65% | -- | -- | -100.00% | 88,077.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.65% | 789.61% | -2.26% | -119.42% | 386,066.67% |
| Foreign Exchange rate Adjustments | 107.49% | -812.97% | 144.99% | 13.72% | -158.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.10% | 266.77% | -16.38% | -176.01% | 417.25% |